金吾财讯 | 四环医药(00460)公告，集团旗下非全资附属公司轩竹生物科技股份有限公司（“轩竹生物”）研发的创新药吡洛西利(Bireociclib)取得了重大科研突破，其联合氟维司群治疗HR+╱HER2-晚期乳腺癌临床III期研究（BRIGHT-2，NCT05077449）期中分析结果，已正式刊登于顶级期刊Nature子刊《Nature Communications》。BRIGHT-2研究是由中国医学科学院肿瘤医院徐兵河院士牵头开展的随机双盲III期试验。该试验聚焦中国乳腺癌患者，他们普遍诊断年龄小、分期晚，LuminalB型比例高，晚期化疗应用多，复发风险大。在此次试验里，吡洛西利联合氟维司群疗效显着。中位随访8.7个月时，联合组中位PFS达12.94个月，远超氟维司群组的7.29个月。各亚组患者均有PFS获益，尤其是内分泌原发耐药、单纯骨转移、肝转移患者风险降低明显，联合组客观缓解率为39.7%，能使肿瘤缩小，缓解症状，带来生存获益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.